Article

Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in severe COVID-19

2023-06-21

Abstract excerpt

Pulmonary infection with SARS-CoV-2 stimulates host immune responses and can also result in the progression of dysregulated and critical inflammation. Throughout the pandemic, the management and treatment of COVID-19 has been continuously updated with a range of antiviral drugs and immunomodulators. Monotherapy with oral antivirals has proven to be effective in the treatment of COVID-19. However, the treatment sho...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2a2fe519-4ea5-5d47-96da-6390def2433a
DOI: 10.1101/2023.06.20.545832

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in severe COVID-19DOI 10.1101/2023.06.20.545832Read

Dexamethasone Ameliorates Severe Pneumonia But Slightly Enhances Viral Replication in Lung of SARS-CoV-2-Infected Syrian HamsterSemantic proximity Read

Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19Semantic proximity Read

Acute respiratory distress syndrome (ARDS) caused by the novel coronavirus disease (COVID-19): a practical comprehensive literature review.Semantic proximity Read

Insights into standards of care – dexamethasone and antibodies against COVID-19 in hamster modelsSemantic proximity Read

Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic InterventionsSemantic proximity Read

The efficacy of combination therapies including antiviral drugs, methylprednisolone and daily proning in 20 patients with COVID-19 requiring invasive mechanical ventilation—Case series in a single critical care center in Osaka, JapanSemantic proximity Read

A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir Vs Currently Used Therapy in Severe COVID-19 Adults. (COMVIVIR, clinicaltrials.gov NCT04475991)Semantic proximity Read

Therapeutic Approaches for COVID-19 Based on the Dynamics of Interferon-mediated Immune ResponsesSemantic proximity Read

COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe casesSemantic proximity Read

A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application.Semantic proximity Read

A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults. “COMVIVIR” Trial.Semantic proximity Read

Differential Immunometabolism and Tissue Responses to Delta and Omicron SARS-CoV-2 Variants in Golden Syrian Hamster ModelsSemantic proximity Read